Table 2 Correlations between CLDN18.2 expression levels and the clinicopathological features of gastric cancer patients
From: CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
Variables | CLDN18.2 expression | Total | Positive rate | χ2 | P value | |
|---|---|---|---|---|---|---|
Positive | Negative | |||||
Age (year) | ||||||
 ≥ 65 | 117 | 95 | 212 | 55.2% | 0.121 | 0.728 |
 < 65 | 128 | 111 | 239 | 53.6% | ||
Sex | ||||||
 Female | 67 | 54 | 121 | 55.4% | 0.073 | 0.787 |
 Male | 178 | 152 | 330 | 53.9% | ||
Family history (gastric cancer) | ||||||
 Yes | 25 | 16 | 41 | 61% | 0.381 | 0.537 |
 No | 180 | 142 | 322 | 55.9% | ||
Smoking history | ||||||
 Yes | 55 | 53 | 108 | 50.9% | 1.925 | 0.165 |
 No | 150 | 105 | 255 | 58.8% | ||
Drinking history | ||||||
 Yes | 43 | 35 | 78 | 55.1% | 0.073 | 0.787 |
 No | 162 | 123 | 285 | 56.8% | ||
Weight loss | ||||||
 Yes | 59 | 47 | 106 | 55.7% | 0.057 | 0.811 |
 No | 146 | 110 | 256 | 57.0% | ||
Tumour location | ||||||
 Proximal stomach | 84 | 59 | 143 | 58.7% | 2.755 | 0.252 |
 Distal stomach | 149 | 140 | 289 | 51.6% | ||
 Total stomach | 11 | 6 | 17 | 64.7% | ||
Borrmann type | ||||||
 I/II | 81 | 48 | 129 | 62.8% | 3.617 | 0.057 |
 III/IV | 120 | 109 | 229 | 52.4% | ||
Lauren type | ||||||
 Intestinal | 142 | 105 | 247 | 57.5% | 5.642 | 0.060 |
 Diffuse | 66 | 74 | 140 | 47.1% | ||
 Mixed | 36 | 21 | 57 | 63.2% | ||
Tumour size (cm) | ||||||
 ≥ 5 | 137 | 119 | 256 | 53.5% | 0.250 | 0.617 |
 < 5 | 104 | 82 | 186 | 55.9% | ||
Grade of differentiation | ||||||
 Well or Moderate | 40 | 38 | 78 | 51.3% | 3.369 | 0.186 |
 Moderate-poor | 84 | 51 | 135 | 62.2% | ||
 Poor | 115 | 100 | 215 | 53.5% | ||
Pathological type | ||||||
 Adenocarcinoma | 231 | 186 | 417 | 55.4% | 2.562 | 0.109 |
 Others | 14 | 20 | 34 | 41.2% | ||
pT stage | ||||||
 T1/2 | 19 | 24 | 43 | 44.2% | 2.022 | 0.155 |
 T3/4 | 220 | 176 | 396 | 55.6 | ||
pN stage | ||||||
 N0/1 | 73 | 71 | 144 | 50.7% | 1.213 | 0.271 |
 N2/3 | 166 | 129 | 295 | 56.3% | ||
pM stage | ||||||
 M0 | 220 | 186 | 406 | 54.2% | 0.141 | 0.707 |
 M1 | 19 | 14 | 33 | 57.6% | ||
pTNM stage | ||||||
 Ι/II | 45 | 37 | 82 | 54.9% | 0.008 | 0.930 |
 III/IV | 194 | 163 | 357 | 54.3% | ||
AFP (ng/ml) | ||||||
 > 8.1 | 10 | 10 | 20 | 50% | 0.432 | 0.511 |
 ≤ 8.1 | 180 | 133 | 313 | 57.5% | ||
CEA (ng/ml) | ||||||
 > 5 | 48 | 38 | 86 | 57% | 0.038 | 0.845 |
 ≤ 5 | 142 | 107 | 249 | 55.8% | ||
CA199 (U/ml) | ||||||
 > 37 | 56 | 44 | 100 | 56% | 0.030 | 0.863 |
 ≤ 37 | 134 | 101 | 235 | 57% | ||
CA724 (U/ml) | ||||||
 > 6.9 | 26 | 29 | 55 | 47.3% | 2.874 | 0.090 |
 ≤ 6.9 | 157 | 106 | 263 | 59.7% | ||
CA125 (U/ml) | ||||||
 > 35 | 12 | 6 | 18 | 66.7% | 0.635 | 0.425 |
 ≤ 35 | 161 | 121 | 282 | 57.1% | ||
CA50 (U/ml) | ||||||
 > 25 | 26 | 17 | 43 | 60.5% | 0.283 | 0.595 |
 ≤ 25 | 129 | 101 | 230 | 56.1% | ||
HER2 | ||||||
 Positive | 17 | 24 | 41 | 41.5% | 3.006 | 0.083 |
 Negative | 228 | 182 | 410 | 55.6% | ||
PD-L1 | ||||||
 Positive | 74 | 38 | 112 | 66.1% | 8.287 | 0.004* |
 Negative | 171 | 168 | 339 | 50.4% | ||